Racura Oncology (ASX:RAC) EBIT: A$-11.73 Mil (TTM As of Dec. 2025)

What is Racura Oncology EBIT?

Racura Oncology ASX:RAC -5.96% 31 EBIT is A$-11.73 Mil as of Dec. 2025. GuruFocus rates ASX:RAC with a GF Score™ of 31/100.

Racura Oncology's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2025 was A$-6.01 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was A$-11.73 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Racura Oncology's annualized ROC % for the quarter that ended in Dec. 2025 was -374.98%. Racura Oncology's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was %.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Racura Oncology's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -2.67%.

Racura Oncology (ASX:RAC) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Racura Oncology's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

	ROC % (Q: Dec. 2025 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2025 )	+	Invested Capital (Q: Dec. 2025 ))	/ count )
=	-12.022 * ( 1 - 0% )	/	( (2.691	+	3.721)	/ 2 )
=	-12.022	/	3.206
=	-374.98 %

where

	Invested Capital		(Q: Jun. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	17.49	-	1.294	-	( 13.666	-	max(0, 1.454	-	14.959	+	13.666	))
=	2.691

	Invested Capital		(Q: Dec. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	24.767	-	0.972	-	( 20.942	-	max(0, 1.156	-	21.23	+	20.942	))
=	3.721

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Racura Oncology's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2025 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jun. 2025		Q: Dec. 2025
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-12.022	/	( ( (0 + max(-0.191, 0))	+	(0 + max(-0.868, 0)) )	/	2 )
=	-12.022	/	( ( 0	+	0 )	/	2 )
=	-12.022	/	0
=	%

where Working Capital is:

	Working Capital		(Q: Jun. 2025 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	1.263)	-	(1.294	+	0	+	0.16)
=	-0.191

	Working Capital		(Q: Dec. 2025 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.032	+	0	+	0.256)	-	(0.972	+	0	+	0.184)
=	-0.868

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Racura Oncology's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2025 )
	=	-11.726	/	439.820
	=	-2.67 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Racura Oncology EBIT Related Terms

Racura Oncology EBIT Historical Data

* Premium members only.

The historical data trend for Racura Oncology's EBIT can be seen below:

Racura Oncology EBIT Chart

Racura Oncology Annual Data

Trend

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Jun25

EBIT

Get a 7-Day Free Trial

-6.78

-11.96

-13.65

-18.66

-10.83

Racura Oncology Semi-Annual Data
	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24	Jun25	Dec25
EBIT	Get a 7-Day Free Trial															-10.13	-8.53	-5.12	-5.72	-6.01

ASX:RAC vs VRTX, REGN, ALNY: EBIT Comparison

For the Biotechnology subindustry, Racura Oncology's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Racura Oncology EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Racura Oncology's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Racura Oncology's EV-to-EBIT falls into.

Save Embed

31GF Score

Racura Oncology Ltd ASX:RAC

EBIT is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Racura Oncology EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-11.73 Mil.

Frequently Asked Questions Learn more about EBIT →

What does a EBIT of A$-11.73 Mil mean?

Racura Oncology (ASX:RAC) has a EBIT of A$-11.73 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Racura Oncology.

Is Racura Oncology's EBIT too high?

Racura Oncology's current EBIT is A$-11.73 Mil. Overall, Racura Oncology has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.

How does Racura Oncology's EBIT compare to VRTX and REGN?

Racura Oncology's EBIT of A$-11.73 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EBIT for a Biotechnology company?

A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EBIT mean?

A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Racura Oncology. Racura Oncology's current EBIT is A$-11.73 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Racura Oncology stock overvalued right now?

Racura Oncology (ASX:RAC) has a current EBIT of A$-11.73 Mil. The current EBIT is A$-11.73 Mil. Racura Oncology's overall GF Score™ is 31/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EBIT calculated?

EBIT is calculated from a company's financial statements. For Racura Oncology (ASX:RAC), the current EBIT is A$-11.73 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Racura Oncology Business Description

Industry Healthcare Biotechnology

Comparable Companies ASX:CUV ASX:TTX ASX:SPL ASX:OCC ASX:RCE ASX:ACW ASX:NYR ASX:ILA ASX:DXB ASX:ATH VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Other Exchanges FN3:Germany

Address 1 Macquarie Place, Level 36, Gateway, Sydney, NSW, AUS, 2000

Website https://www.racuraoncology.com

Racura Oncology Ltd is a developer of an oncology therapeutics platform designed to develop targeted cancer treatments. The company offers precision oncology drug development, biomarker-driven research, and cancer metabolism therapies, enabling healthcare providers and cancer patients to access targeted treatment options with improved therapeutic outcomes.

31GF Score

Get the complete analysis for ASX:RAC

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$2.21

Price

View ASX:RAC Analysis

See EBIT data for all stocks →